DSpace@İnönü

Imatinib mesylate in first-line treatment of chronic myeloid leukemia

Basit öğe kaydını göster

dc.contributor.author Ekinci, Omer
dc.contributor.author Kizilkaya, Ismet
dc.date.accessioned 2022-03-07T16:39:40Z
dc.date.available 2022-03-07T16:39:40Z
dc.date.issued 2019
dc.identifier.citation Ekinci, O., & Kizilkaya, I. (2021). Imatinib mesylate in first-line treatment of chronic myeloid leukemia . Annals of Medical Research en_US
dc.identifier.uri http://hdl.handle.net/11616/54556
dc.description.abstract Aim: Sixty nine patients who were diagnosed with CML and were treated with first-generation TKI ( in the form of imatinib mesylate) as initial treatment between 2006 and 2018 were included in this retrospective study. The demographic characteristics, response rates (hematologic, cytogenetic and molecular), adverse events and overall survival (OS) rates were retrospectively analyzed.Results: There were 28 male and 41 female patients with a median age of 49.3. Hematologic, cytogenetic and molecular responses to TKI treatment were evaluated according to the 2013 guidelines of European Leukemia Net (ELN). The complete hematologic response (CHR) rate at three months was 97.1%, the complete cytogenetic response (CCR) rate at 12 months was 73.4%, and the major molecular response (MMR) at 18 months was 77.8%. The most common adverse events were cytopenia (13%), edema (10.1%), nausea/vomiting (7.2%), and musculoskeletal pain (5.8%). The mean follow-up period was 40.4 months for all CML patients, with an overall survival (OS) rate of 84.6% during follow-up.Conclusion: As a real life data in our population, our results were consistent with those reported in the literature. Drug-related adverse events were minimal and tolerable. Long-term survival and disease-free survival can be achieved with proper cytogenetic and molecular monitoring under imatinib treatment and, if necessary, a change in medication. en_US
dc.language.iso eng en_US
dc.rights info:eu-repo/semantics/openAccess en_US
dc.title Imatinib mesylate in first-line treatment of chronic myeloid leukemia en_US
dc.type article en_US
dc.relation.journal Annals of Medical Research en_US
dc.contributor.department İnönü Üniversitesi en_US


Bu öğenin dosyaları:

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster